Omnicell, Inc. OMCL R2KR3KPHARMA

Q: What is the current share price of Omnicell, Inc. (OMCL)?

As of 2026-09-07 16:24 PDT, Omnicell, Inc. (OMCL) trades at $34.37 on NasdaqGS. Its 52-week range is $29.46 to $51.39.

Q: What is the market capitalisation of OMCL?

Omnicell, Inc. (OMCL) has a market capitalisation of $1.57B on NasdaqGS.

Q: What is the P/E ratio of OMCL?

OMCL trades at a trailing price-to-earnings (P/E) ratio of 40.92. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.33.

Q: What is the return on equity (ROE) of OMCL?

OMCL has a return on equity (ROE) of 3.06%. Its return on capital employed (ROCE) is 0.34%.

Q: Is OMCL a good stock to buy?

This page provides a data-driven analysis of Omnicell, Inc. (OMCL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Health Information Services · United States

https://www.omnicell.com

Company Profile ↓

$34.37

+9.67% 1Y

Mkt Cap$1.57B

P/E40.92

P/B1.33

52W High$51.39

52W Low$29.46

Book Value$27.63

EPS (TTM)$0.84

Company Overview

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 10.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.3% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.15.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $1.18B (+6.5% YoY); net profit $2.05M.
Trailing 12 Months Year-on-year growth — revenue +7.5%, earnings +333.3%.
5-Year Trend Long-term compounding — revenue CAGR 11.3%, profit CAGR 10.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	11.31%
1 Year:	7.50%

Compounded Profit Growth

5 Years:	10.04%
1 Year:	333.30%

Stock Price Performance

1 Year:	+9.67%
6 Months:	-16.78%
3 Months:	-20.07%
1 Month:	-4.95%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 22% of range

$29.46 $51.39

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)40.31 · Neutral

Price Performance

1M-4.95%

3M-20.07%

6M-16.78%

1Y+9.67%

Valuation vs Sector

P/E of 40.92 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 11.3% over 5 years.
Profit CAGR of 10.0% over 5 years.
Generates positive free cash flow.

CONS

Trading 33.1% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

40.92

Industry PE

25.17

Forward P/E

16.44

PEG Ratio

15.40

Book Value

$27.63

Price to Book

1.33

P/S

1.35

EV/EBITDA

16.09

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

11.31%

Profit 5Y

10.04%

Revenue (YoY)

7.50%

Earnings (YoY)

333.30%

Profitability & Returns

ROCE

0.34%

ROE

3.06%

ROA

1.99%

Profit Margin

3.14%

Op Margin

10.91%

Gross Margin

45.27%

EPS (Latest Qtr)

$0.52

EPS (TTM)

$0.84

Balance Sheet & Liquidity

Debt/Equity

0.15

Quick Ratio

1.16

Current Ratio

1.64

Debt

$188.51M

Total Assets

$2.00B

Current Assets

Working Capital

Ownership

Promoter Holding

2.15%

Chg in Prom Hold

-0.10%

FII / Inst Holding

108.28%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$1.57B

Total Revenue (TTM)

$1.25B

EBITDA

$97.81M

Free Cash Flow

$155.01M

Operating Cash Flow

$181.44M

Shares Outstanding

45.61M

Gross Margin

45.27%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	OMCL Omnicell, Inc. R2KR3KPHARMA	34.37	40.92	$1.57B	0.00%	0.34%	3.06%	11.31%	10.04%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2013	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	202.52M	217.41M	228.81M	229.69M	199.62M	213.70M	251.84M	272.74M	296.40M	318.83M	331.39M	348.06M	290.63M	298.97M	298.66M	246.15M	276.79M	282.42M	269.67M	290.56M	310.63M	309.88M	312.21M
Gross Profit	49.37M	52.04M	54.49M	56.04M	59.55M	61.69M	57.46M	63.70M	79.94M	78.02M	81.51M	62.19M	78.13M	84.82M	82.45M	88.78M	98.91M	97.12M	104.05M	112.15M	109.62M	83.22M	96.79M	122.28M	136.30M	146.78M	150.05M	158.09M	159.09M	125.03M	134.44M	131.96M	92.62M	114.35M	122.27M	110.94M	127.68M	134.50M	140.36M	152.94M
Operating Income	9.36M	10.72M	9.95M	12.56M	13.60M	10.38M	12.42M	13.86M	1.85M	-118.00K	4.93M	-16.55M	-701.00K	12.20M	633.00K	7.33M	17.50M	12.76M	18.76M	24.65M	12.15M	-6.99M	10.15M	19.61M	28.92M	29.39M	5.08M	12.48M	18.46M	-22.96M	7.75M	3.71M	-21.85M	3.22M	6.56M	-11.62M	8.12M	8.24M	16.85M	32.45M
Net Income	-	-	6.19M	7.79M	7.30M	6.32M	8.75M	8.04M	-378.00K	-1.16M	1.98M	-10.34M	1.88M	7.75M	2.72M	6.59M	13.63M	3.28M	15.98M	19.98M	11.31M	-4.30M	8.80M	14.13M	20.42M	29.32M	8.21M	9.07M	16.77M	-15.00M	3.45M	5.55M	-15.68M	3.73M	8.63M	-7.02M	5.64M	5.46M	11.36M	24.29M
Diluted EPS	0.17	0.21	0.17	0.21	0.20	0.17	0.24	0.22	-0.01	-0.03	0.05	-0.28	0.05	0.20	0.07	0.16	0.33	0.08	0.37	0.46	0.26	-0.10	0.20	0.30	0.43	0.61	0.17	0.20	0.37	-0.33	0.08	0.12	-0.34	0.08	0.19	-0.15	0.12	0.12	0.25	0.52
R&D Expense	7.15M	6.56M	6.12M	6.47M	7.08M	8.02M	8.75M	9.18M	13.84M	13.79M	15.26M	16.80M	16.91M	16.41M	16.54M	15.51M	15.80M	16.08M	16.85M	16.62M	18.65M	20.83M	15.20M	16.08M	18.21M	19.48M	25.03M	26.36M	25.17M	22.88M	23.14M	24.28M	22.06M	21.10M	21.21M	20.53M	21.57M	24.02M	21.52M	20.30M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	213.46M	222.41M	245.53M	314.03M	380.58M	440.90M	484.56M	695.91M	712.71M	787.31M	897.03M	892.21M	1.13B	1.30B	1.15B	1.11B	1.18B
Gross Profit	105.22M	117.92M	135.78M	170.59M	203.40M	233.86M	247.93M	317.08M	318.64M	372.33M	436.91M	413.29M	554.65M	588.99M	496.84M	471.00M	503.44M
Operating Income	669.00K	9.53M	16.22M	27.13M	35.30M	49.58M	48.63M	21.41M	11.14M	44.39M	78.35M	35.53M	89.51M	-2.32M	-34.87M	337.00K	5.16M
Net Income	444.00K	4.89M	10.39M	16.18M	23.98M	30.52M	30.76M	9.76M	30.52M	37.73M	61.34M	32.19M	77.85M	5.65M	-20.37M	12.53M	2.05M
Diluted EPS	0.01	0.15	0.30	0.47	0.67	0.83	0.84	0.26	0.79	0.93	1.43	0.74	1.62	0.12	-0.45	0.27	0.04
R&D Expense	17.57M	21.01M	22.04M	23.73M	29.11M	27.80M	35.16M	57.80M	66.02M	64.84M	68.64M	70.16M	75.72M	104.97M	97.11M	90.41M	88.67M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	343.22M	363.85M	441.82M	492.50M	560.21M	578.75M	935.10M	1.02B	1.08B	1.24B	1.82B	2.14B	2.21B	2.23B	2.12B	1.97B
Total Equity	233.56M	242.30M	265.21M	282.91M	307.55M	349.00M	390.10M	420.46M	458.84M	554.34M	679.62M	845.25M	967.50M	1.15B	1.13B	1.19B	1.24B	1.23B
Cash & Equivalents	120.44M	169.23M	175.63M	191.76M	62.31M	104.53M	125.89M	82.22M	54.49M	32.42M	67.19M	127.21M	485.93M	349.05M	330.36M	467.97M	369.20M	196.52M
Long Term Debt	-	-	-	-	-	-	-	0	245.73M	194.92M	135.42M	50.00M	-	-	-	-	-	-
Total Liabilities	-	-	78.01M	80.94M	134.27M	143.50M	170.12M	176.36M	503.50M	462.02M	401.62M	395.56M	857.00M	995.81M	1.08B	1.04B	877.65M	742.91M
Current Liabilities	-	-	58.16M	60.63M	83.08M	92.40M	112.33M	124.63M	180.91M	205.21M	204.58M	237.00M	276.42M	876.16M	428.45M	367.79M	595.68M	476.61M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	39.48M	55.26M	65.16M	38.49M	49.90M	24.83M	103.97M	145.01M	185.87M	231.81M	77.78M	181.09M	187.72M	127.30M
Investing Cash Flow	-	-	-	-168.71M	-20.45M	-43.33M	-45.60M	-341.32M	-34.99M	-54.37M	-61.66M	-279.87M	-412.50M	-58.67M	-55.02M	-52.79M	-60.36M
Financing Cash Flow	-	-	-	-232.00K	7.37M	-206.00K	-36.56M	263.75M	-9.88M	-13.60M	-23.48M	456.27M	47.36M	-20.95M	23.42M	-235.58M	-218.32M
Capital Expenditure	-3.65M	-6.89M	-8.69M	-15.12M	-12.34M	-11.92M	-7.54M	-13.45M	-15.34M	-23.70M	-15.89M	-22.84M	-28.97M	-47.54M	-41.47M	-36.46M	-40.41M
Free Cash Flow	-	-	-	24.36M	42.93M	53.24M	30.94M	36.45M	9.49M	80.27M	129.11M	163.03M	202.84M	30.25M	139.62M	151.26M	86.89M
Share Buybacks	-	0	12.57M	12.36M	20.96M	24.09M	50.02M	0	0	0	0	53.03M	0	52.21M	0	0	77.60M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	49.3%	53.0%	55.3%	54.3%	53.4%	53.0%	51.2%	45.6%	44.7%	47.3%	48.7%	46.3%	49.0%	45.4%	43.3%	42.3%	42.5%
Operating Margin %	0.3%	4.3%	6.6%	8.6%	9.3%	11.2%	10.0%	3.1%	1.6%	5.6%	8.7%	4.0%	7.9%	-0.2%	-3.0%	0.0%	0.4%
Net Margin %	0.2%	2.2%	4.2%	5.2%	6.3%	6.9%	6.3%	1.4%	4.3%	4.8%	6.8%	3.6%	6.9%	0.4%	-1.8%	1.1%	0.2%
ROE %	0.2%	1.8%	3.7%	5.3%	6.9%	7.8%	7.3%	2.1%	5.5%	5.6%	7.3%	3.3%	6.8%	0.5%	-1.7%	1.0%	0.2%
ROCE %	-	3.3%	5.3%	7.6%	8.8%	11.1%	10.7%	2.8%	1.4%	5.1%	7.8%	2.3%	7.1%	-0.1%	-1.9%	0.0%	0.3%

Shareholding Pattern

Insiders

2.15%

Institutions

108.28%

Public Float

110.65%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	16.58%	7.54M	$249.41M
2	Vanguard Portfolio Management LLC	6.93%	3.15M	$104.25M
3	Wellington Management Group, LLP	5.94%	2.70M	$89.34M
4	Dimensional Fund Advisors LP	5.39%	2.45M	$81.13M
5	State Street Corporation	4.59%	2.09M	$69.00M
6	Vanguard Capital Management LLC	4.33%	1.97M	$65.18M
7	Millennium Management Llc	3.81%	1.73M	$57.37M
8	Nomura Asset Management International Inc	3.53%	1.61M	$53.14M
9	Geode Capital Management, LLC	2.68%	1.22M	$40.25M
10	Nuveen, LLC	2.26%	1.03M	$34.04M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for OMCL

Google News Mon, 03 Aug 2026

Omnicell (OMCL) Stock May Be 42% Below Fair Value On Weak Guidance - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOQlloXzVwUUFCTEsxLWNyakdSelhTR3NzaVdmRzJDeHIzRUJkRTlXazNOclZpZkxrUTBESXgxMlJhbTlvZ0N6VDVxcjc0N0RwRmw4cFZmU2VZQmpVY0NJcDc0bUNxSlg0dmwydW5aNm9tMU5kSV9iNjJLUmd1RDJWbEo5ZUZueVZPRjBoNU…

Google News hu, 03 Sep 2026

A new integration lets hospitals check medicines as they arrive - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTHJIWkdrRW45TDNIMzR1S0NsMm5GUUF4WXcyMy00N3RNaXBxbzBXZ3pPZXBTZFhWVTdYSzlILWZsWlZUcFlGZEtpaGR5akV4RWpxS0Z6S0t5c3ZYTm9ZTTl0cF9tS2JRSExPWmxDR3pqZW9TcF9WX040VlJGWS1QVk5WdlRIeWdIQ1pXOF…

Google News Sat, 05 Sep 2026

Does Embedding TraceLink’s DSCSA Tools Into Omnicell Workflows Reframe Its Cloud and Recurring Revenue Story (OMCL)? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPSUk0RmJwemJ6YV9hUkpmX05uT2JOczZDRVJfLXpSOXpfSTVpWHZFRW01X1g5R09EVXpjOHpBeXg3cHJBazRJTlZaT1JxakQxd1BOZlhoX2RMaHhnUXk4S2RuU3JjXzBneFNKeVNYSEIzdHFxRjFWMEo1a2dLMW15bVB0MERtNzd1eHBjMV…

Google News Wed, 27 May 2026

OMCL - Omnicell Inc Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBqUEI5cjdockY0cUZrREQ0X2Fjdnl4YUpBRkdpd1pVQ2NsQ1MwcXE1QnFSVFhoWFhvTk03LWM1NVVhRUlmVUE?oc=5" target="_blank">OMCL - Omnicell Inc Stock Price and Quote</a>  <font color="#6…

Google News hu, 25 Jun 2026

OMCL Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1qaVVUb2pnMVR2VVpBSVEweGJPNDNwc19rWDA1eXF4cGNLdzFBcVMxa0xfclJSSUw2dmUzZXBtSEZSV2VnQkE4b2VzdlJwNXVlLXRVZFg5MjVEdW5Ua3ZVQUtXenNYZm9vQjZLTnZfR1hVMWhHZ2hTNDFn?oc=5" target="_blank">OMC…

Google News hu, 03 Sep 2026

OMCL Looks 9.4% Undervalued on GF Value™ - GuruFocus

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxNMU4zaHRLLUU1VG5rVU9hZ0FHNWdnNmhYcGNhMzdXTUJOMEhrcFRjTEF0VVZ6bVdhdHdtcnNEUzdLc3kwQ0RveURoMlJBNGF3S2pHR05ZbC1XZldHa2JyQjdac01JUWtqUmNsemdpdVB1b3Y2azVqVUlQU0ZVY2pYbHF3?oc=5" target=…

OMCL — Frequently Asked Questions

What is the current share price of Omnicell, Inc. (OMCL)?

As of 2026-09-07 16:24 PDT, Omnicell, Inc. (OMCL) trades at $34.37 on NasdaqGS. Its 52-week range is $29.46 to $51.39.

What is the market capitalisation of OMCL?

Omnicell, Inc. (OMCL) has a market capitalisation of $1.57B on NasdaqGS.

What is the P/E ratio of OMCL?

OMCL trades at a trailing price-to-earnings (P/E) ratio of 40.92. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.33.

What is the return on equity (ROE) of OMCL?

OMCL has a return on equity (ROE) of 3.06%. Its return on capital employed (ROCE) is 0.34%.

Is OMCL a good stock to buy?

This page provides a data-driven analysis of Omnicell, Inc. (OMCL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Omnicell, Inc. OMCL R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Omnicell (OMCL) Stock May Be 42% Below Fair Value On Weak Guidance - Yahoo Finance

A new integration lets hospitals check medicines as they arrive - Stock Titan

Does Embedding TraceLink’s DSCSA Tools Into Omnicell Workflows Reframe Its Cloud and Recurring Revenue Story (OMCL)? - simplywall.st

OMCL - Omnicell Inc Stock Price and Quote - Finviz

OMCL Forecast — Price Target — Prediction for 2027 - TradingView

OMCL Looks 9.4% Undervalued on GF Value™ - GuruFocus

OMCL — Frequently Asked Questions

What is the current share price of Omnicell, Inc. (OMCL)?

What is the market capitalisation of OMCL?

What is the P/E ratio of OMCL?

What is the return on equity (ROE) of OMCL?

Is OMCL a good stock to buy?

Explore More